Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Processa Pharmaceuticals ( (PCSA) ) has shared an announcement.
On September 2, 2025, Processa Pharmaceuticals, Inc. held a Special Shareholder Meeting in Pasadena, CA, but adjourned it due to lack of quorum. The meeting is rescheduled for September 12, 2025, in Vero Beach, FL, with no changes to the proposals or record date for voting.
The most recent analyst rating on (PCSA) stock is a Buy with a $1.00 price target. To see the full list of analyst forecasts on Processa Pharmaceuticals stock, see the PCSA Stock Forecast page.
Spark’s Take on PCSA Stock
According to Spark, TipRanks’ AI Analyst, PCSA is a Underperform.
Processa Pharmaceuticals is facing significant financial challenges with no revenue generation and ongoing losses. Technical indicators point to bearish momentum, and valuation metrics highlight the high-risk nature typical of early-stage biotech firms. The company’s reliance on external financing for sustainability remains a concern.
To see Spark’s full report on PCSA stock, click here.
More about Processa Pharmaceuticals
Processa Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing drugs for unmet medical needs.
Average Trading Volume: 18,459,078
Technical Sentiment Signal: Strong Sell
Current Market Cap: $9.52M
See more data about PCSA stock on TipRanks’ Stock Analysis page.